Agalsidase-Beta Therapy for Advanced Fabry DiseaseMaryam Banikazemi, Robert J. Desnick, Jan Bultas et al.|Annals of Internal Medicine|2007Cited by 565
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick diseaseKenichi Horinouchi, Edward H. Schuchman, Colin L. Stewart et al.|Nature Genetics|1995Cited by 477
Functional variants in the <i>LRRK2</i> gene confer shared effects on risk for Crohn’s disease and Parkinson’s diseaseKen Hui, Judy H. Cho, Heriberto Fernandez-Hernandez et al.|Science Translational Medicine|2018Cited by 411
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyRaphael Schiffmann, Robert J. Desnick, David G. Warnock et al.|Nephrology Dialysis Transplantation|2009Cited by 366
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Gabor E. Linthorst et al.|Journal of Medical Genetics|2015Cited by 363